EGFR and non-small cell lung carcinoma: A phase 1 trial is evaluating the efficacy of CAR-T cells targeting EGFR in patients with advanced-stage NSCLC (NCT05060796), where the therapy was mostly well-received except for a significant increase in serum lipase levels graded 3–4.